FDA Clears Adicet's IND for ADI-212 in Prostate Cancer
ACET sits 49% above its 52-week low of $6.01.
Summary
Adicet Bio received FDA clearance to begin clinical trials for ADI-212, a gene-edited CAR T therapy for metastatic castration-resistant prostate cancer. The company plans to start Phase 1 enrollment in Q4 2026. This is a new pipeline asset for Adicet, which recently reported Q2 results and a timeline for its lead asset prula-cel. The IND clearance validates the company's expansion into solid tumors and adds a near-term clinical catalyst. Investors will watch for initial safety and efficacy data from the Phase 1 trial.
At the time of this announcement, ACET was trading at $8.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84M. The 52-week trading range was $6.01 to $17.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.